Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paediatric bronchiectasis phenotypes and their association with clinical outcomes: development and validation in two prospective clinical cohorts.

Thorax·2026
Same author

Neutrophil-related gene expression profile is associated with future paediatric bronchiectasis exacerbations.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

Improving asthma control assessment and outcomes in children with asthma using an artificial intelligence digital tool: a prospective multicentre cohort study.

ERJ open research·2026
Same author

Development of a paediatric severity score to predict outcomes of radiographic-confirmed community-acquired pneumonia in hospitalised children in Sabah, Malaysia.

Archives of disease in childhood·2026
Same author

Short and long-term effects of a play-based therapeutic exercise programme in children with non-cystic fibrosis bronchiectasis: A randomised controlled trial.

Journal of science and medicine in sport·2026
Same author

Improving the management and outcomes of preschool wheeze: protocol of a prospective multicentre cohort study.

BMJ open respiratory research·2026

Related Experiment Videos

Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled

Patricia C Valery1, Peter S Morris, Keith Grimwood

  • 1Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. patricia.valery@menzies.edu.au

BMC Pediatrics
|August 16, 2012
PubMed
Summary
This summary is machine-generated.

This study investigated if weekly azithromycin reduces lung exacerbations in Indigenous children with bronchiectasis. Results will inform long-term antibiotic use for this condition.

Related Experiment Videos

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Clinical Trials

Background:

  • High prevalence of chronic suppurative lung disease (CSLD) and bronchiectasis in Indigenous children across Australia, New Zealand, and Alaska.
  • Antibiotics are a cornerstone of CSLD management, with long-term use aimed at reducing pulmonary exacerbations.
  • Limited evidence exists on the efficacy of long-term antibiotic therapy for pediatric CSLD and non-cystic fibrosis bronchiectasis.

Purpose of the Study:

  • To test the hypothesis that weekly maintenance azithromycin reduces pulmonary exacerbations in Indigenous children with bronchiectasis.
  • To provide evidence supporting the use of long-term antibiotics for managing bronchiectasis in this vulnerable population.

Main Methods:

  • Multicenter, randomized, double-blind, placebo-controlled trial in Australia and New Zealand.
  • Inclusion of Indigenous children aged 1-8 years with diagnosed bronchiectasis and at least one exacerbation in the past year.
  • Randomization to weekly azithromycin (30 mg/kg) or placebo for 12-24 months, with primary outcomes being exacerbation rate and time to exacerbation.

Main Results:

  • Primary outcomes: rate and time to pulmonary exacerbations.
  • Secondary outcomes: exacerbation severity, growth, school absenteeism, respiratory symptoms, lung function (FEV1), and sputum characteristics.
  • Safety endpoints include serious adverse events and monitoring of antibiotic resistance.

Conclusions:

  • The trial aims to determine the efficacy of azithromycin in reducing pulmonary exacerbations.
  • Positive findings would establish a rationale for long-term antibiotic use in pediatric bronchiectasis management for Indigenous children.